These days, a patient searching online for weight management treatment might come across two websites that look equally legitimate. One may belong to a regulated pharmacy, while the other may be a criminal imitation. This is a real risk for people accessing healthcare online because many patients cannot easily tell the difference between a licensed provider and a cloned site designed to exploit their trust. That risk is growing as criminals increasingly copy online pharmacy websites, social media accounts, regulator logos, and even health advice content in order to sell counterfeit weight loss medicines. The scale of the problem is significant, with the National Pharmacy Association (NPA) reporting that one in 10 online pharmacies has had its website or social media presence cloned to trick patients into buying counterfeit weight loss medication.
It is important not to lose sight of what legitimate online pharmacies can offer when they are properly regulated. They can be safe, clinically governed, and accessible, and they play a vital role in widening access to care when they operate within the right regulatory and clinical frameworks. The challenge now is that the same digital environment that makes healthcare more convenient also makes it easier for criminals to mimic trusted providers. That leaves the sector with a clear question, which is how to make safe, regulated care easier for patients to recognise.
The Black Market
Has Moved On The black market for medicines is increasingly presented through search results, social media posts, private messages, and websites designed to look professional, when they are in fact cloned.
This is also growing into public discourse around next-generation incretin medicines, including investigational treatments such as retatrutide – better understood as a triple hormone receptor agonist still under clinical investigation, rather than as a medicine currently available through routine prescribing.
As public awareness grows around future medicines before they are approved or legally available outside clinical trials, criminals may see an opportunity to exploit demand before patients understand what is legitimate.
One patient reportedly bought a counterfeit Mounjaro pen from a site posing as a pharmacy for a quarter of the market price. Another received a GLP-1 medicine labelled for another patient and sent without a needle. At the same time, interest in retatrutide shows how quickly demand can form around medicines before they are available through lawful, regulated routes.
